Medicines and treatments for preventing deadly syndromes like cancer, HIV and Influenza are yet far-flung in many regions of the world and factors like expensiveness; less availability and inadequate scope for new drugs are likely to be responsible for this outlying existence of such medicines. However, in a recent breakthrough, a team of international researchers have found out a new protein which may soon serve as the saviour of victims of deadly diseases like HIV, Cancer and Influenza.
A team of US-based scientists, in their most recent step forward, has discovered a ground-breaking protein that may make the vaccinations more effective and provide unyielding protection from life-injuring diseases like cancer, HIV and influenza. The research, conducted by a team of scientists from Boston University’s school of medicine has developed a protein, called ‘PorB’ – generally found on the exterior of bacteria known as Neisseria meningidis and claimed that it could provide protection against the above-described syndromes. Moreover, the protein can also be used it as an addition to offering a better immunisation response.
In general, vaccines can either amplify the quantity of antibody production in the body or can encourage the cells called cytotoxic T cell, to directly slaughter the antisocial agents in the body, responsible for the programming of diseases. In the case of cancer, HIV, and Influenza, the protein, is exceptional because it can do both – enlarge the amount of antibody production in the body and also can stimulate the cytotoxic T cells, said the co-author of the study Lee Wetzler from Boston University’s school of medicine.
Adding to the statement, Lee Wetzler said, “The study has some valuable suggestions about the protein – PorB as it can not only be employed for helping the body to recognize and defend against bacterial infections, but also can potentially aid the body to use its own apparatus to fight off syndromes like cancer, HIV and influenza, far before they started enrooting in the body.” The findings are detailed in the journal of Scientific Reports, published over this weekend.
For the study, the team brought two experimental models into play. The first model was to give an immunisation with antigen and mixed PorB, whereas the second mould was to provide the antigen alone. After analysing the study, researchers found that, the model that received the combined effect of antigen and PorB had an increased response to the vaccine antigen, and amplified the number of activated cells in the lymph nodes as well as documented as effective for the invention of cytotoxic T cells whereas the inoculation with the antigen alone are found to be less useful for stimulating such factors. The study focuses more on deepening the understanding about how vaccine adjuvant transforms immune responses in the body.